There were 1,596 press releases posted in the last 24 hours and 398,541 in the last 365 days.

Evolus to Report Second Quarter 2019 Financial Results and Provide a Business Update on Monday, August 12, 2019

NEWPORT BEACH, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its second quarter 2019 financial results and provide a business update on Monday, August 12, 2019 prior to open of U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 8:00 a.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers.  The conference ID is 4298762.

A replay of the call will be available following its completion through August 19, 2019. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 4298762.

A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau®(prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.

Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contacts:
Ashwin Agarwal
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com

Media Contacts:
Crystal Muilenburg
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.